<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="937">
  <stage>Registered</stage>
  <submitdate>12/12/2005</submitdate>
  <approvaldate>14/12/2005</approvaldate>
  <actrnumber>ACTRN12605000790640</actrnumber>
  <trial_identification>
    <studytitle>Deep breaths and airway closure in asthma</studytitle>
    <scientifictitle>Effect of inhaled surfactant on the magnitude of bronchoprotection by deep inspiration against methacholine induced airway narrowing in asthmatic and non-asthmatic subjects</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Asthma</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Poractant alfa, 120mg delivered by aerosolization of a 50mg/ml suspension in  0.9% normal saline, on two occasions administered 30 minutes before bronchial challenge with methacholine chloride.</interventions>
    <comparator>Control solution is 0.9% normal saline, delivered by aerosolization on two occasions administered 30 minutes before bronchial challenge with methacholine chloride.</comparator>
    <control>Placebo</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The fall in the forced expiratory volume in one second, with and without deep inspirations.</outcome>
      <timepoint>Measured 60 seconds after bronchial challenges with methacholine, after active and control treatments.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The bronchoprotective effect of deep inspiration, measured by the difference in response between tests with and without deep inspirations, after active and control treatments.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Asthma, defined by previous doctor diagnosis and current symptoms or regular therapyNon-asthmatic controls with no history of asthma or other chronic respiratory disease.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Smokers and subjects who are otherwise unsuitable for bronchial challenge will be excluded.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Random allocation sequence generated and kept by an independent researcher in a password protected file</concealment>
    <sequence>Random number generator in Microsoft Excel used to determine treatment sequence</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>1/02/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Woolcock Institute of Medical Research</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Woolcock Institute of Medical Research</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney South West Area Health Service (RPAH Zone)</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Cheryl Salome</name>
      <address>Woolcock Institute of Medical Research
PO Box M77
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 95158383</phone>
      <fax>+61 2 95506115</fax>
      <email>cms@woolcock.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sarah Newton-John</name>
      <address>PO Box M77
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 95156578</phone>
      <fax>+61 2 95505865</fax>
      <email>sarahnj@woolcock.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>